2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1155

Economic Impact of Frequent Gout Flares in a Managed Care Setting
Abstract Number: 1144

Economic Implications for Policies Regarding Triple Therapy Use in Patients with Rheumatoid Arthritis
Abstract Number: 1147

Economic Implications of Flares Among Patients with Early Rheumatoid Arthritis (RA)
Abstract Number: 1973

Ectopic Lymphoid Neogenesis Is Strongly Associated with Activation of the IL-23/IL-17 Pathway in Rheumatoid Synovitis
Abstract Number: 13

Eculizumab in Antiphospholipid Antibody Syndrome
Abstract Number: 2195

Eculizumab Treatment of Malignant Atrophic Papulosis (Köhlmeier-Degos Disease): World Experience to Date
Abstract Number: 2858

Education Effects on Outcome Expectations for Exercise in Adults with Knee Osteoarthritis
Abstract Number: 1375

Educational Level and Not Ethnicity an Important Determinant of Disease Progression in Patients with Rheumatoid Arthritis
Abstract Number: 512

Effect and Safety of Concomitant Methotrexate and Tacrolimus on Clinical Response of Abatacept in Rheumatoid Arthritis Patients with Prior Use of Biological Dmards
Abstract Number: 2028

Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The Espoir Cohort
Abstract Number: 179

Effect of Allopurinol on All-Cause Mortality in Adults with Incident Gout: Propensity Score Matched Landmark Analysis
Abstract Number: 2854

Effect of Apremilast on Quality of Life and Physical Function in Patients with Behçet’s Syndrome
Abstract Number: 565

Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
Abstract Number: 687

Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus—the Hopkins Lupus Cohort
Abstract Number: 1847

Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate in the Preserve Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].